Olanzapine depot formulation in rat: A step forward in modelling antipsychotic-induced metabolic adverse effects

International Journal of Neuropsychopharmacology

Volumn 17, Issue 1, 2014, Pages 91-104

  Skrede, Silje ^a,b   Martins, Luís ^c,d   Berge, Rolf Kristian ^a   Steen, Vidar Martin ^a,b   López, Miguel ^c,d   Ferno, Johan ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^d Instituto de Salud Carlos III   (Spain)

Author keywords

AMPK; antipsychotics; depot injection; hyperphagia; rats

Indexed keywords

BETA ACTIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MESSENGER RNA; OLANZAPINE; PHOSPHOLIPID; PROTEIN FASN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BENZODIAZEPINE DERIVATIVE; DELAYED RELEASE FORMULATION; NEUROLEPTIC AGENT;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARCUATE NUCLEUS; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; ENZYME INHIBITION; FEMALE; FOOD INTAKE; HYPERPHAGIA; HYPOTHALAMUS; HYPOTHALAMUS VENTROMEDIAL NUCLEUS; INTRAABDOMINAL FAT; LIPID METABOLISM; LIPOGENESIS; METABOLIC DISORDER; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; STRESS; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WHITE ADIPOSE TISSUE; ADIPOSE TISSUE; ADMINISTRATION AND DOSAGE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; DELAYED RELEASE FORMULATION; DISEASE MODEL; DRUG EFFECTS; EATING; ENZYMOLOGY; GENE EXPRESSION; GENE SILENCING; GENETICS; LIVER; METABOLISM; PHARMACOKINETICS;

ADIPOSE TISSUE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIPSYCHOTIC AGENTS; ARCUATE NUCLEUS OF HYPOTHALAMUS; BENZODIAZEPINES; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; EATING; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; LIVER; METABOLIC DISEASES; RATS; TRIGLYCERIDES; VENTROMEDIAL HYPOTHALAMIC NUCLEUS; WEIGHT GAIN;

EID: 84888599281     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713000862     Document Type: Article

References (59)

1. Ahnaou A, Megens AA, Drinkenburg WH (2003) The atypical antipsychotics risperidone, clozapine and olanzapine differ regarding their sedative potency in rats. Neuropsychobiology 48:47-54. (Pubitemid 36928715)
2. Albaugh VL, Henry CR, Bello NT, Hajnal A, Lynch SL, Halle B, Lynch CJ (2006) Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring) 14:36-51. (Pubitemid 46214773)
3. American Diabetes Association APA, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 65:267-272.
4. Aravagiri M, Teper Y, Marder SR (1999) Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 20:369-377. (Pubitemid 30449775)
5. Arjona AA, Zhang SX, Adamson B, Wurtman RJ (2004) An animal model of antipsychotic-induced weight gain. Behav Brain Res 152:121-127. (Pubitemid 38597070)
6. Baptista T, Mata A, Teneud L, de Quijada M, Han HW, Hernandez L (1993) Effects of long-term administration of clozapine on body weight and food intake in rats. Pharmacol Biochem Behav 45:51-54.
7. Boyda HN, Tse L, Procyshyn RM, Honer WG, Barr AM (2010) Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol Sci 31:484-497.
8. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM (1999) Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 37:177-193.
9. Canfran-Duque A, Casado ME, Pastor O, Sanchez-Wandelmer J, de la Pena G, Lerma M, Mariscal P, Bracher F, Lasuncion MA, Busto R (2013) Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro. J Lipid Res 54(2):310-324.
10. Cannon B, Nedergaard J (2004) Brown adipose tissue: function and physiological significance. Physiol Rev 84:277-359. (Pubitemid 38054374)
11. Choi S, DiSilvio B, Unangst J, Fernstrom JD (2007) Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats. Life Sci 81:1024-1030. (Pubitemid 47384786)
12. Coccurello R, Moles A (2010) Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther 127:210-251.
13. Cooper GD, Pickavance LC, Wilding JP, Halford JC, Goudie AJ (2005) A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl) 181:80-89. (Pubitemid 41440918)
14. Cooper GD, Pickavance LC, Wilding JP, Harrold JA, Halford JC, Goudie AJ (2007) Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J Psychopharmacol 21:405-413. (Pubitemid 47077303)
15. Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, Rosenheck R, Davis SM, Hsiao JK, Stroup TS, Lieberman JA (2008) Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 105:175-187.
16. Davoodi N, Kalinichev M, Korneev SA, Clifton PG (2009) Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine. Psychopharmacology (Berl) 203:693-702.
17. Fell MJ, Neill JC, Rao C, Marshall KM (2005) Effects of sub-chronic antipsychotic drug treatment on body weight and reproductive function in juvenile female rats. Psychopharmacology (Berl) 182:499-507. (Pubitemid 41464631)
18. Fell MJ, Anjum N, Dickinson K, Marshall KM, Peltola LM, Vickers S, Cheetham S, Neill JC (2007) The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Psychopharmacology (Berl) 194:221-231. (Pubitemid 47457949)
19. Ferno J, Raeder MB, Vik-Mo AO, Skrede S, Glambek M, Tronstad KJ, Breilid H, Lovlie R, Berge RK, Stansberg C, Steen VM (2005) Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J 5:298-304. (Pubitemid 41486229)
20. Ferno J, Vik-Mo AO, Jassim G, Havik B, Berge K, Skrede S, Gudbrandsen OA, Waage J, Lunder N, Mork S, Berge RK, Jorgensen HA, Steen VM (2009) Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology (Berl) 203:73-84.
21. Ferno J, Varela L, Skrede S, Vazquez MJ, Nogueiras R, Dieguez C, Vidal-Puig A, Steen VM, Lopez M (2011) Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation. PLoS ONE 6:e20571. doi: 10.1371/journal.pone. 0020571.
22. Goudie AJ, Smith JA, Halford JC (2002) Characterization of olanzapine-induced weight gain in rats. J Psychopharmacol 16:291-296. (Pubitemid 35470572)
23. Jassim G, Skrede S, Vazquez MJ, Wergedal H, Vik-Mo AO, Lunder N, Dieguez C, Vidal-Puig A, Berge RK, Lopez M, Steen VM, Ferno J (2012) Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. Psychopharmacology (Berl) 219:783-794.
24. Kalinichev M, Rourke C, Daniels AJ, Grizzle MK, Britt CS, Ignar DM, Jones DN (2005) Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Psychopharmacology (Berl) 182:220-231. (Pubitemid 41464615)
25. Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell D (2010) Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 167:181-189.
26. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH (2007) From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 104:3456-3459. (Pubitemid 46364180)
27. Kristiana I, Sharpe LJ, Catts VS, Lutze-Mann LH, Brown AJ (2010) Antipsychotic drugs upregulate lipogenic gene expression by disrupting intracellular trafficking of lipoprotein-derived cholesterol. Pharmacogenomics J 10:396-407.
28. Lage R, Dieguez C, Vidal-Puig A, Lopez M (2008) AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med 14:539-549.
29. Lopez M, Lelliott CJ, Vidal-Puig A (2007) Hypothalamic fatty acid metabolism: a housekeeping pathway that regulates food intake. Bioessays 29:248-261. (Pubitemid 46384164)
30. Lopez M et al. (2010) Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med 16:1001-1008.
31. Lopez M et al. (2008) Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metab 7:389-399. (Pubitemid 351618114)
32. Mann S, Chintoh A, Giacca A, Fletcher P, Nobrega J, Hahn M, Remington G (2013) Chronic olanzapine administration in rats: effect of route of administration on weight, food intake and body composition. Pharmacol Biochem Behav. 103(4):717-722.
33. Martinez de Morentin PB, Whittle AJ, Ferno J, Nogueiras R, Dieguez C, Vidal-Puig A, Lopez M (2012) Nicotine induces negative energy balance through hypothalamic AMP-activated protein kinase. Diabetes 61:807-817.
34. Martins L, Fernandez-Mallo D, Novelle MG, Vazquez MJ, Tena-Sempere M, Nogueiras R, Lopez M, Dieguez C (2012) Hypothalamic mTOR signaling mediates the orexigenic action of ghrelin. PLoS ONE 7:e46923. doi:10.1371/journal/pone. 0046923.
35. Martins PJ, Haas M, Obici S (2010) Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance. Diabetes 59:2418-2425.
36. Mattiuz E, Franklin R, Gillespie T, Murphy A, Bernstein J, Chiu A, Hotten T, Kassahun K (1997) Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. Drug Metab Dispos 25:573-583. (Pubitemid 27213098)
37. McGrath J, Saha S, Chant D, Welham J (2008) Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 30:67-76.
38. McNamara RK, Jandacek R, Rider T, Tso P, Cole-Strauss A, Lipton JW (2011) Atypical antipsychotic medications increase postprandial triglyceride and glucose levels in male rats: relationship with stearoyl-CoA desaturase activity. Schizophr Res 129:66-73.
39. Minet-Ringuet J, Even PC, Goubern M, Tome D, de Beaurepaire R (2006) Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration. Appetite 46:254-262. (Pubitemid 43867820)
40. Minet-Ringuet J, Even PC, Valet P, Carpene C, Visentin V, Prevot D, Daviaud D, Quignard-Boulange A, Tome D, de Beaurepaire R (2007) Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. Mol Psychiatry 12:562-571. (Pubitemid 46816768)
41. Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, Mu J, Foufelle F, Ferre P, Birnbaum MJ, Stuck BJ, Kahn BB (2004) AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428:569-574. (Pubitemid 38480541)
42. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW (2006) Central nervous system control of food intake and body weight. Nature 443:289-295. (Pubitemid 44435142)
43. Perez-Costas E, Guidetti P, Melendez-Ferro M, Kelley JJ, Roberts RC (2008) Neuroleptics and animal models: feasibility of oral treatment monitored by plasma levels and receptor occupancy assays. J Neural Transm 115: 745-753.
44. Puntel M, Kroeger KM, Sanderson NS, Thomas CE, Castro MG, Lowenstein PR (2010) Gene transfer into rat brain using adenoviral vectors. Curr Protoc Neurosci Chapter 4:Unit 4 24.
45. Remington G, Mann S, McCormick P, Nobrega JN, Hahn M, Natesan S (2011) Modeling chronic olanzapine exposure using osmotic minipumps: pharmacological limitations. Pharmacol Biochem Behav 100:86-89.
46. Reynolds GP, Kirk SL (2010) Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther 125:169-179.
47. Robertson MD, McMullin MM (2000) Olanzapine concentrations in clinical serum and postmortem blood specimens-when does therapeutic become toxic? J Forensic Sci 45:418-421. (Pubitemid 30158420)
48. Sanchez-Wandelmer J, Hernandez-Pinto AM, Cano S, Davalos A, de la Pena G, Puebla-Jimenez L, Arilla-Ferreiro E, Lasuncion MA, Busto R (2009) Effects of the antipsychotic drug haloperidol on the somastostatinergic system in SH-SY5Y neuroblastoma cells. J Neurochem 110:631-640.
49. Sejima E, Yamauchi A, Nishioku T, Koga M, Nakagama K, Dohgu S, Futagami K, Kataoka Y (2011) A role for hypothalamic AMP-activated protein kinase in the mediation of hyperphagia and weight gain induced by chronic treatment with olanzapine in female rats. Cell Mol Neurobiol 31:985-989.
50. Shobo M, Yamada H, Koakutsu A, Hamada N, Fujii M, Harada K, Ni K, Matsuoka N (2011) Chronic treatment with olanzapine via a novel infusion pump induces adiposity in male rats. Life Sci 88:761-765.
51. Skrede S, Ferno J, Bjorndal B, Brede WR, Bohov P, Berge RK, Steen VM (2012a) Lipid-lowering effects of tetradecylthioacetic acid in antipsychotic-exposed, female rats: challenges with long-term treatment. PLoS ONE 7:e50853. doi:10.1371/journal/pone/0050853.
52. Skrede S, Ferno J, Vazquez MJ, Fjaer S, Pavlin T, Lunder N, Vidal-Puig A, Dieguez C, Berge RK, Lopez M, Steen VM (2012b) Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. Int J Neuropsychopharmacol 15:163-179.
53. Skrede S, Steen VM, Ferno J (2013) Antipsychotic-induced increase in lipid biosynthesis: activation through inhibition? J Lipid Res 54:307-309.
54. Summerly R, Yardley H (1965) The effect of a substituted fluorobutyrophenone (haloperidol) on the metabolism of sterols in rat skin. Biochem J 96:30.
55. van der Zwaal EM, Luijendijk MC, Adan RA, la Fleur SE (2008) Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution. Eur J Pharmacol 585:130-136.
56. Varela L, Martinez-Sanchez N, Gallego R, Vazquez MJ, Roa J, Gandara M, Schoenmakers E, Nogueiras R, Chatterjee K, Tena-Sempere M, Dieguez C, Lopez M (2012) Hypothalamic mTOR pathway mediates thyroid hormone-induced hyperphagia in hyperthyroidism. J Pathol 227:209-222.
57. Vik-Mo AO, Birkenaes AB, Ferno J, Jonsdottir H, Andreassen OA, Steen VM (2008) Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. Int J Neuropsychopharmacol 11:679-684. (Pubitemid 351931824)
58. Weston-Green K, Huang XF, Deng C (2010) Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats. Behav Brain Res 217:337-346.
59. Whittle AJ, Carobbio S, Martins L, Slawik M, Hondares E, Vazquez MJ, Morgan D, Csikasz RI, Gallego R, Rodriguez-Cuenca S, Dale M, Virtue S, Villarroya F, Cannon B, Rahmouni K, Lopez M, Vidal-Puig A (2012) BMP8B increases brown adipose tissue thermogenesis through both central and peripheral actions. Cell 149: 871-885.